Back to search

National and Kapodistrian University of Athens

Προσδιορισμός πρωτεϊνών φαρμακευτικής αντίστασης και τοποϊσομερασών Ι και ΙΙ σε ασθενείς με καρκίνο παχέος εντέρου που έχουν υποβληθεί σε χημειοθεραπεία

Abstract

dc:description

Purpose: To investigate whether chemotherapy with 5-FU induces an alteration in the levels of Pgp, MRP and LRP, which are multidrug resistance-related proteins, as well as in the levels of topoisomerase IIα and topoisomerase I, in patients with colorectal cancer. Patients and methods: Our study included 40 patients with colorectal cancer who underwent surgical resection of the primary tumour, received chemotherapy with 5-FU plus leucovorin according to the Mayo Clinic regimen, and then recurred and underwent a second surgery. Therefore, we had two specimens from each patient: one from the primary location (before chemotherapy) and a second one from the recurrence (after chemotherapy). The presence of the three multidrug resistance-related proteins and topoisomerase I and IIα before and after chemotherapy with 5-FU was studied by means of standard three-step imunohistochemistry on paraffin sections, using appropriate monoclonal antibodies. Immunostaining for each protein was estimated both semiquantitatively (graded according to the percentage of tumor cells staining positive) and quantitatively (the percentage of tumor cells staining positive was calculated by an image analysis system). We used McNemar's paired chi-square test to assess the possible alteration of the levels of each protein after chemotherapy with 5-FU, according to the semiquantitative estimation. We used Wilcoxon matched-pairs signed-ranks test to assess the possible alteration of the levels of each protein after chemotherapy with 5-FU, according to the quantitative estimation. Results: The expression of Pgp, MRP and LRP did not change significantly after chemotherapy with 5-FU, neither with the semiquantitative (p=0.5959, p=0.5403, p=0.2301 respectively), nor with the quantitative (p=0.476, p=0.643, p=0.122 respectively) estimation. On the contrary, there was a statistical significant increase in the levels of topoisomerase IIα and topoisomerase I (p<0.0001 with both the semiquantitative and the quantitative estimation). Discussion: The increase of topoisomerase IIα in cancer cells after chemotherapy with 5-FU doesn’t seem to have clinical significance. Topoisomerase IIα is the molecular target of widely used antineoplastic drugs, like anthracyclines and epipodophyllotoxins, which are not used in chemotherapy of colorectal cancer and are substrates of Pgp, MRP and LRP. The increase of topoisomerase I has clinical significance, as the enzyme is the molecular target of irinotecan, a drug widely used in chemotherapy of colorectal cancer. In general, irinotecan is not susceptible to multidrug resistance.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2008

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Gouveris, Panagiotis
  • Γκούβερης, Παναγιώτης

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/23891

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Gouveris, Panagiotis; Γκούβερης, Παναγιώτης. Προσδιορισμός πρωτεϊνών φαρμακευτικής αντίστασης και τοποϊσομερασών Ι και ΙΙ σε ασθενείς με καρκίνο παχέος εντέρου που έχουν υποβληθεί σε χημειοθεραπεία. National and Kapodistrian University of Athens, 2008. http://hdl.handle.net/10442/hedi/23891